Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Read More
Neil Desai, PhD
Management of adverse events in the AMPECT trial of
nab
-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Read More
Richard Maroun, JD
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (
nab
-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
Antitumor activity of
nab
-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
Synergistic Antitumor Activity of
nab
-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.